Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
June 2016 Share this issue Facebook LinkedIn Twitter
>
I New BNF eNewsletter - succinct and easier to read
>
I Welcome
Welcome to the June BNF eNewsletter.
This month we include news of three new drug monographs, including albiglutide and ramucirumab. Along with new NICE technology appraisals for ezetimibe, abiraterone, and others, you'll find updated guidance for the management of obesity, breast cancer and prostate cancer. We outline cautions for the use of paracetamol in patients with risk factors for hepatotoxicity and low body-weight.

Our BNF Case Study considers the treatment options available to manage the symptoms of uncontrolled chronic asthma.

In response to your feedback in the recent survey we have redesigned the eNewsletter to make it clearer, more succinct and easier to use. We'd welcome your thoughts - let us know in the Feedback section at the end of the eNewsletter.
Kind regards,
BNF Team
I In this issue
Significant changes More >  
News More >  
Drug safety update More >  
How to purchase BNF More >  
Price reminder More >  
Feedback More >  
I Significant
changes
This month's changes to the clinical content of these publications are described in three parts:

BNF & BNFC update should be read by all users of the BNF or BNF for Children
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 71
BNF BNF for Children Updates
Obesity: updated guidance on management
For further information, see Obesity.
Paracetamol: clarification of cautions in patients with risk factors for hepatotoxicity and low body-weight
For further information, see Paracetamol.
BNF for Children Update
Other changes
To review other changes in the BNFC, click on changes.
BNF Updates
Breast cancer: updated guidance on management
For further information, see Breast cancer.
Prostate cancer: updated guidance on management
For further information, see Prostate cancer.
NICE technology appraisals
A number of NICE technology appraisals have been added to the BNF this month, including:
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
For a list of all NICE technology appraisals added in this update, see changes.
Albiglutide: new drug monograph
For further information, see Albiglutide.
Pembrolizumab: new drug monograph
For further information, see Pembolizumab.
Ramucirumab: new drug monograph
For further information, see Ramucirumab.
Other changes
To review other changes in the BNF, click on changes.
I News
BNF Case Study: Managing uncontrolled asthma
Our BNF Case Study can help you put BNF advice on the management of chronic asthma into practice.
BNF - did you know?
There were nearly 37 million online page views over the last year, in 129 countries around the world. Worldwide, in a 24-hour span, an average of 211 people per hour will be using BNF on MedicinesComplete - with each user spending an average of 5.35 minutes per session. Usage of the app has increased, to more than 5.3 million uses over the last twelve months - keeping you informed and up to date with the latest developments.
BNF 71
BNF online
Changes to 'Clarifications and corrections' on bnf.org
We have retired the 'Clarifications and corrections' page that was set up for BNF 70. All future clarifications and corrections will be displayed on the news page under Clinical news. Keep up to date with clarifications, corrections, and updates to BNF Publications here.
BNF - help from the CPPE
An interactive PDF e-learning programme from CPPE is designed to help users familiarise themselves with new recommendations and the latest information in BNF 71. It consists of 10 case studies, and can be accessed here. CPPE have also produced a guide to using the BNF, which you can access on their website here.
CPPE
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2016 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
>
BNF is also available as an eBook.
More
We offer preferential pricing for bulk orders and for members of various professional associations. So if you are buying on behalf of a CCG, Health Board, NHS Trust or other organisation, contact us here. GPs should contact their CCG direct, who can obtain a discount when placing a centralised bulk order.
I Monthly price update reminder
Prices of all branded medicinal products in the BNF and BNFC are now updated monthly. Prices of generic preparations of medicinal products are updated every 2-4 months, to coincide with print editions of BNF and BNF for Children. The BNF team keep price information up to date using data sourced from the NHS dictionary of medicines and devices (dm+d).
I Feedback on our eNewsletter
Please let us know if there are any issues that you’d like us to address in our eNewsletters, and if you have any comments on the new design. We welcome your feedback. If you have any comments or suggestions, please let us know at enewsletter@bnf.org.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2016 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2016 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.